{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=10", "query": { "intervention": "tenofovir disoproxil/emtricitabine", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 339, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:24:31.230Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00112047", "title": "Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Emtricitabine (FTC)", "type": "DRUG" }, { "name": "Tenofovir Disoproxil Fumarate (TDF)", "type": "DRUG" }, { "name": "Efavirenz (EFV)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "FTC/TDF/EFV", "type": "DRUG" }, { "name": "Lamivudine/zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2003-07", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2010-10-13", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 5, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112047" }, { "nct_id": "NCT00959894", "title": "Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Etravirine (Intelence)", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2009-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959894" }, { "nct_id": "NCT05108935", "title": "Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use", "Opioid Use Disorder", "Risk Reduction", "Hiv", "Hepatitis C" ], "interventions": [ { "name": "Suboxone", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" }, { "name": "Mavyret", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-02-17", "completion_date": "2023-03-30", "has_results": false, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 2, "location_summary": "Durham, North Carolina • Greensboro, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05108935" }, { "nct_id": "NCT01641809", "title": "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1265744 10 mg", "type": "DRUG" }, { "name": "GSK1265744 30 mg", "type": "DRUG" }, { "name": "GSK1265744 60 mg", "type": "DRUG" }, { "name": "Efavirenz 600 mg", "type": "DRUG" }, { "name": "Rilpivirine 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-08-06", "completion_date": "2019-01-15", "has_results": true, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641809" }, { "nct_id": "NCT06333808", "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match BIC/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 577, "start_date": "2024-03-25", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06333808" }, { "nct_id": "NCT01854775", "title": "Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TAF (Low Dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2013-05-06", "completion_date": "2025-06-18", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 5, "location_summary": "Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854775" }, { "nct_id": "NCT02707601", "title": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection", "HCV Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "F/R/TAF", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-04-01", "completion_date": "2017-09-29", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707601" }, { "nct_id": "NCT00262522", "title": "Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Infections" ], "interventions": [ { "name": "lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 664, "start_date": "2005-11", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2012-02-06", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262522" }, { "nct_id": "NCT03960645", "title": "Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "FEMALE", "summary": "18 Years to 39 Years · Female only" }, "enrollment_count": 62, "start_date": "2019-06-28", "completion_date": "2022-08-18", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 2, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03960645" }, { "nct_id": "NCT01701895", "title": "Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV-1 Infection" ], "interventions": [], "intervention_types": [], "sponsor": "Prema Menezes, PhD, PA-C", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2012-10", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-12-02", "last_synced_at": "2026-10-14T01:24:31.230Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701895" } ] }